Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2024

Implementation of a Research Platform to Facilitate Clinical Trials and Research in South Western Sydney Local Health District (SWSLHD) (#507)

Gui Xiong 1 2 , Erfan Jaberiyanfar 2 3 , Nasreen Kaadan 1 2 , Jonathan Dahmer 4 , Ryan Luhan 2 3 , Angela Berthelsen 1 2 , Mahbuba Sharmin 1 2 , John Frew 1 5 , Georgina Kennedy 1
  1. Cancer Services, SWSLHD, Liverpool, NSW, Australia
  2. Ingham Institute, Liverpool, NSW, Australia
  3. Clinical Trial Support Unit, SWSLHD, Liverpool, NSW, Australia
  4. TriNetX, Cambridge, Massachusetts, United States of America
  5. Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia

Background:

Clinical trials are essential to establishing evidence-based treatments that lead to better outcomes for patients.1 Low patient recruitment for clinical trials can lead to delays, early trial termination, or inability to draw conclusions.2,3 Insufficient recruitment to clinical trials results in missed opportunities for patients who can benefit from clinical trials, wastes time, funds, and other resources.4,5
In SWSLHD, low clinical trial recruitment was attributed to systematic barriers in identifying eligible patients for recruitment, including:

  • fragmented patient data across multiple clinical information systems (CIS).
  • dependency on CIS reporting teams to identify patient numbers/lists.

Aim:

To implement a research platform, TriNetX, to address identified recruitment barriers:

  • To combine CIS data into TriNetX
  • For the Clinical Trial Support Unit (CTSU) to self-report using TriNetX

Method:

Implementation stages:

Stage 1

  • Set up a database configuration for PowerChart data
  • Establish data feed from the database into TriNetX
  • Map PowerChart data within TriNetX
  • User acceptance testing (UAT)

Stage 2

  • Repeat Stage 1 for Mosaiq data

Stage 3

  • Merge CIS data within TriNetX
  • Final UAT

A Phase 3 soft-go-live allowed for early access to TriNetX to begin identifying trial cohorts and recruit patients for clinical trials and research projects.

Results:

Since TriNetX implementation:

  • 46 cohort self-reported, of which 31 were for oncology.
  • Cohort take 30mins–3hours to self-report.
  • 75% of requests have informed of viable trial protocols, provided cohort population information, and informed trial feasibility.
  • 26 clinical trials connected to SWSLHD via the platform.
  • 1 clinical trial protocol designed using the platform.
  • 2 academic publications in progress using the platform.

Conclusion:

The implementation of the research platform builds the capability of the CTSU workforce to collate information from multiple CIS. The CTSU team is successfully self-reporting through the platform, on near real-time data, to identify cohorts and recruit patients for clinical trials and research projects.

 

  1. Unger JM, Cook E, Tai E, Bleyer A (2016) 'The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies', American Society of Clinical Oncology Educational Book, 35, pp 185-98. DOI:10.1200/EDBK_156686
  2. Nipp RD, Hong K, Paskett ED (2019) 'Overcoming Barriers to Clinical Trial Enrolment', American Society of Clinical Oncology Educational Book, 39, pp 105-114. DOI:10.1200/EDBK_243729
  3. Carlisle B, Kimmelman J, Ramsay T, MacKinnon N (2015) 'Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials', Clinical Trials, 12(1), pp 77-83. DOI:10.1177/1740774514558307
  4. Wong AR, Sun V, George K, Liu J, Padam S, Chen BA, George T, Amini A, Li D, Sedrak MS (2020) 'Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists', JCO Oncology Practice, 16, pp 849-858. DOI:10.1200/JOP.19.00662
  5. Wandile P (2023) 'Patient Recruitment in Clinical Trials: Areas of Challenges and Success, a Practical Aspect at the Private Research Site' Journal of Biosciences and Medicines, 11(10), pp 103-113. DOI:10.4236/jbm.2023.1110010.